SENTI-202

Phase 1Biologic

SSenti Biosciences

SENTI-202 is one of 5 biologic programs targeting Blood Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blood CancerActive, not recruiting

Blood CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Blood Cancer

#DrugCompanyPhaseTrials

Jaypirca

Eli Lilly

Phase 2

1 2

COVID-19 Vaccine

Moderna

Phase 2

1 3

Koselugo

AstraZeneca

Phase 1

1 4

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

1 5

SENTI-202

SSenti Biosciences

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2040

Phase 1Active, not recruiting

Blood Cancer

NCT06325748

Clinical

Trials by Indication[1]

Blood Cancer1 trial

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Active, not recruiting·SSenti Biosciences·Phase 1·NCT06325748·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SENTI-202. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SENTI-202 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SENTI-202. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Senti Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSenti Biosciences

SENTI-202

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2040

Trials by Indication[1]

Blood Cancer1 trial

References

Drug Info

Quick Facts

Related News